WCLC 2016 | Updated Data from Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer
Shirish Gadgeel, MD, from Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, provides us with updated information on a North American study (NP28761) evaluating alectinib in patients with ALK–positive Non–Small–Cell Lung Cancer (NSCLC) who are resistant to crizotinib, the first line ALK inhibitor.
Based on results from several studies, alectinib has been approved in the US and Japan for the treatment of patients who have progressed on or are intolerant to crizotinib.
Shirish Gadgeel gives us an overview of the results from the updated study that had a longer 17-month follow-up than the primary analysis. The study showed that the response rate for alectinib was about 52%, the response rate in patients with measurable CNS metastases was 75%, the medium progression-free survival (PFS) was approximately 8.5 months and the overall survival of patients enrolled on this trail was about 22 months.
He mentions how this study confirms the activity already observed with alectinib in ALK-positive NSCLC patients previously treated with crizotinib and the next step is to wait for results of the global on-going ALEX study, which is comparing alectinib to crizotinib as an initial first-line treatment for ALK-Positive NSCLC patients. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Get great new content delivered to your inboxSign up